Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I
Public ClinicalTrials.gov record NCT01172808. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 µg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 µg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma
Study identification
- NCT ID
- NCT01172808
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 1,071 participants
Conditions and interventions
Conditions
Interventions
- 50 mcg salmeterol HFA MDI Drug
- Placebo Drug
- tiotropium Respimat® high dose Drug
- tiotropium Respimat® low dose Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2010
- Primary completion
- Oct 31, 2012
- Completion
- Oct 31, 2012
- Last update posted
- Jun 8, 2014
2010 – 2012
United States locations
- U.S. sites
- 21
- U.S. states
- 14
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 205.418.01020 Boehringer Ingelheim Investigational Site | Huntington Beach | California | — | — |
| 205.418.01002 Boehringer Ingelheim Investigational Site | Mission Viejo | California | — | — |
| 205.418.01014 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 205.418.01011 Boehringer Ingelheim Investigational Site | Wheat Ridge | Colorado | — | — |
| 205.418.01004 Boehringer Ingelheim Investigational Site | Coeur d'Alene | Idaho | — | — |
| 205.418.01017 Boehringer Ingelheim Investigational Site | Normal | Illinois | — | — |
| 205.418.01008 Boehringer Ingelheim Investigational Site | South Bend | Indiana | — | — |
| 205.418.01012 Boehringer Ingelheim Investigational Site | Baltimore | Maryland | — | — |
| 205.418.01013 Boehringer Ingelheim Investigational Site | North Dartmouth | Massachusetts | — | — |
| 205.418.01015 Boehringer Ingelheim Investigational Site | North Dartmouth | Massachusetts | — | — |
| 205.418.01009 Boehringer Ingelheim Investigational Site | Minneapolis | Minnesota | — | — |
| 205.418.01006 Boehringer Ingelheim Investigational Site | Bellevue | Nebraska | — | — |
| 205.418.01016 Boehringer Ingelheim Investigational Site | Boys Town | Nebraska | — | — |
| 205.418.01003 Boehringer Ingelheim Investigational Site | Omaha | Nebraska | — | — |
| 205.418.01021 Boehringer Ingelheim Investigational Site | Winston-Salem | North Carolina | — | — |
| 205.418.01018 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 205.418.01005 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 205.418.01010 Boehringer Ingelheim Investigational Site | Easely | South Carolina | — | — |
| 205.418.01007 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 205.418.01019 Boehringer Ingelheim Investigational Site | Seattle | Washington | — | — |
| 205.418.01001 Boehringer Ingelheim Investigational Site | Tacoma | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 93 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01172808, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 8, 2014 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01172808 live on ClinicalTrials.gov.